Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

• Main Authors: M. Rizzo (Author), S. Pontarollo (Author), F. Tiso (Author), R. Montisci (Author), H. Marotta (Author), F. Tona (Author), S. Iliceto (Author), F. Cozzi (Author)
• Format: Book
• Published: PAGEPress Publications, 2011-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Pulmonary arterial hypertension (PAH) is a rare but severe complication of connective tissue diseases (CTD), with a negative impact on patients survival. Bosentan, a receptor antagonist of endothelin, has been proved effective for the treatment of PAH. The aim of this study was to evaluat...